The vascular endothelial growth factor (VEGF) pathway has several therapeutic targets for tumor angiogenesis.1,2 In 2004, the US Food and Drug Administration (FDA) approved VEGF pathway inhibitors (VPIs) for the treatment of malignant neoplasms such as hepatocellular carcinoma and renal cell carcinoma, as well as their metastases.3 Here, VEGFA is linked to renal cell carcinoma.